On May 10, 2019, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib. Approval was based on REACH‑… Read More
WOBURN, Mass. (June 20, 2019) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres® Y-90 resin microspheres, a treatment for patients with liver cancer.* More than 1,000 healthcare providers and hospital… Read More
June 10, 2019 PALO ALTO, Calif., June 10, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has acquired Austin, Texas-based Endocare and Hangzhou, China-based, Alicon, to expand its portfolio of multidisciplinary integrated cancer care solutions. Endocare is a leading provider of… Read More
Some patients who undergo selective internal radiotherapy (SIRT) with yttrium-90 (Y-90) may be eligible for liver resection, researchers reported. SIRT is typically a palliative procedure, but certain patients have a response that warrants surgical resection with curative intent. To better… Read More
Researchers have identified factors that are linked with increased risk of symptomatic recurrence after radiofrequency ablation for osteoid osteomas. The retrospective cohort analysis took place at a single center and included 71 patients treated with CT-guided radiofrequency ablation from July… Read More
The Society of Interventional Oncology (SIO) recently sent a letter to the National Comprehensive Cancer Network (NCCN) Kidney Cancer Guideline panel seeking changes to proposed guidelines for management of T1a renal masses. The NCCN guidelines are influential among both clinicians and payors, and… Read More
AUSTIN, TX—Transarterial Y-90 radioembolization with resin microspheres using MIRD dosimetry for intrahepatic cholangiocarcinoma appears to be safe and shows promising survival outcomes, researchers from Beth Israel Deaconess Medical Center reported in an abstract presented at SIR. “There is this… Read More
AUSTIN, TX—Patients with metastatic neuroendocrine tumors may potentially be able to consider same-day mapping or no mapping prior to treatment with Y-90 radioembolization, based on the rare incidence of hepatopulmonary shunting in this population. Researchers presented their data in an abstract… Read More
AUSTIN, TX—A systemic review and meta-analysis has found that an average tumor dose of 275 Gy for patients with hepatocellular carcinoma (HCC) treated with Y-90 radioembolization is able to predict objective tumor response. The authors undertook the review and analysis to better understand Y-90… Read More
Liver resection may lead to better outcomes than transarterial chemoembolization (TACE) for cirrhotic patients with resectable intermediate-stage hepatocellular carcinoma (HCC), according to a study published in Cancer Medicine. Although TACE is typically recommended for intermediate-stage HCC,… Read More